The global Leukapheresis market gathered revenue around USD 62 million in 2020 and market is set to grow USD 93 million by the end of 2027 and is estimated to expand at a modest CAGR of 9.2% during the prediction period 2021 to 2027. Leukopaks are enriched leukapheresis products that contain higher concentrations of leukocytes. The increasing incidence and prevalence of leukemia and growing demand for leukopaks for research applications are some of the factors driving the growth of these markets. However, the high cost of therapeutic leukapheresis and cellular therapies, stringent donor recruitment criteria, and long procedural time for leukapheresis are restraining the growth of this market to a certain extent.
This research report purposes at stressing the most lucrative growth prospects. The aim of the research report is to provide an inclusive valuation of the Leukapheresis market and it encompasses thoughtful visions, actualities, industry-validated market findings, historic data, and prognoses by means of appropriate set of assumptions and practice. Global Leukapheresis market report aids in comprehending market structure and dynamics by recognizing and scrutinizing the market sectors and predicted the global market outlook.
COVID-19 Impact Assessment on Market Landscape
The report comprises the scrutiny of COVID-19 lock-down impact on the income of market leaders, disrupters and followers. Since lock down was instigated differently in diverse regions and nations, influence of same is also dissimilar across various industry verticals. The research report offers present short-term and long-term influence on the market to assist market participants across value chain makers to formulate the framework for short term and long-lasting tactics for recovery and by region.
Leukapheresis market report empower readers with all-inclusive market intelligence and offers a granular outline of the market they are operational in. Further this research study delivers exceptional combination of tangible perceptions and qualitative scrutiny to aid companies accomplishes sustainable growth. This report employs industry-leading research practices and tools to assemble all-inclusive market studies, intermingled with pertinent data. Additionally, this report also emphases on the competitive examination of crucial players by analyzing their product portfolio, pricing, gross margins, financial position, growth approaches, and regional occurrence.
Opportunity: Leukapheresis for pediatric patients
Despite its therapeutic applications, the adoption of leukapheresis as a treatment, particularly for hyperleukocytic leukemia, is still low. However, the applications of therapeutic leukapheresis in the treatment of pediatric patients are becoming an area of focus for stakeholders in this sector. This can be mainly attributed to the side-effects and risks of conventional treatments such as chemotherapy for children. Leukapheresis can be used for both the treatment/removal of excess WBCs in pediatric lymphoma patients and the collection of stem cells from children for other cancer patients. The possibilities and advantages of leukapheresis in this application make it an area of focus in this market, particularly given that very few hospitals currently provide leukapheresis treatment for children in both developed as well as emerging markets.
Competitive Rivalry
Foremost players in the market are attentive on adopting corporation strategies to enhance their market share. Some of the prominent tactics undertaken by leading market participants in order to sustain the fierce market completion include collaborations, acquisitions, substantial spending in R&D and the improvement of new-fangled products or reforms among others.
Significant Market Participants Operational in the Leukapheresis Market are:
Some prominent players in The leukopaks market are Charles River Laboratories (US), AllCells, LLC (US), StemExpress, LLC. (US), Caltag Medsystems Limited (UK), Lonza Group AG (Switzerland), ZenBio (US), Precision for Medicine (US), BioIVT (US), Discovery Life Sciences (US), and Intelligent Tissue Group (US).
Unravelling the Critical Segments
This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects including product type, application/end-user, and region. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for period 2017 to 2027 and covers subsequent region in its scope:
The research report categorizes the market into the following segments and subsegments:
Leukapheresis Products Market, By Type
- Leukapheresis Disposables
- Leukapheresis Devices
- Centrifugal Devices
- Membrane Separators
Leukapheresis Products Market, By Application
- Research Applications
- Therapeutic Applications
Leukapheresis Products Market, By End User
- Blood Component Providers & Blood Centers
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
- Hospital & Transfusion Centers
Leukopaks Market, By Type
- Mobilized Leukopaks
- Non-Mobilized Leukopaks
- Diseased Leukopaks
- Isolated PBMCs
Leukopaks Market, By Application
- Mobilized Leukopaks
- Non-Mobilized Leukopaks
- Diseased Leukopaks
- Isolated PBMCs
Leukopaks Market, By Indication
- Acute Lymphocytic Leukemia
- Multiple Myeloma
- Non-Hodgkin’s Lymphoma
- Chronic Lymphocytic Lymphoma
- Pancreatic Cancer
- Hepatocellular Carcinoma
- Other Indications
Leukopaks Market, By End User
- Academic & Research Institutes
- Pharmaceutical & Biotechnology
By Geography
North America
Europe
- Germany
- France
- United Kingdom
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Southeast Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of Middle East & Africa
Request Customization
Get a Sample
Get a Sample
Request Customization